{"id":"peg-p-ifn-alpha-2b-aop2014","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"40-60","effect":"Headache"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression / mood changes"},{"rate":"10-20","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug is a long-acting pegylated form of interferon alpha-2b, which binds to interferon alpha receptors on immune cells and hepatocytes to induce antiviral and immunomodulatory effects. The pegylation extends the drug's half-life, allowing for less frequent dosing. It is primarily used in viral hepatitis and certain malignancies where interferon-based immunotherapy is beneficial.","oneSentence":"Peg-P-IFN-alpha-2b is a pegylated interferon alpha-2b that activates innate immune responses to suppress viral replication and enhance antiviral immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:11.330Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"}]},"trialDetails":[{"nctId":"NCT07468916","phase":"PHASE2","title":"Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-03-29","conditions":"Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":35},{"nctId":"NCT02370329","phase":"PHASE2","title":"P1101 in Treating Patients With Myelofibrosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-08-12","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":11},{"nctId":"NCT02218047","phase":"PHASE3","title":"AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2014-11","conditions":"Polycythemia Vera","enrollment":170},{"nctId":"NCT01949805","phase":"PHASE3","title":"Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2013-09","conditions":"Polycythemia Vera","enrollment":257},{"nctId":"NCT02523638","phase":"PHASE3","title":"Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2015-07","conditions":"Polycythemia Vera","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AOP2014","P1101"],"phase":"phase_3","status":"active","brandName":"Peg-P-IFN-alpha-2b (AOP2014)","genericName":"Peg-P-IFN-alpha-2b (AOP2014)","companyName":"AOP Orphan Pharmaceuticals AG","companyId":"aop-orphan-pharmaceuticals-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peg-P-IFN-alpha-2b is a pegylated interferon alpha-2b that activates innate immune responses to suppress viral replication and enhance antiviral immunity. Used for Chronic hepatitis C, Chronic hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}